August 2018 – We are excited to announce the release of our WIPO Re:Search Mid-Year Report 2018! Over the first half of the year, BVGH established ten new collaborations and recruited five new Members. Read the Report to learn how the BVGH team is well on its way to achieving and surpassing its goals and deliverables for 2018.
(April 2018) Nigeria has stepped up its fight against cancer with the launch of its National Cancer Control Plan 2018-2022. During the inaugural event, BVGH presented the African Access Initiative (AAI) and its alliance with the Nigerian government to address the rapidly rising burden of cancer in the country. Read more here.
(April 2018) Check out MedChemNet’s interview with Dr. Joseph Hargan-Calvopiña and learn how BVGH and WIPO Re:Search are accelerating research and development for neglected tropical diseases (NTDs), malaria, and TB. Watch here.
February 21, 2018 – The Access to Medicine Foundation has worked with BVGH to develop a framework for identifying which IP assets are most likely to accelerate research into the medicines and vaccines needed by people living in low- and middle-income countries.
February 2018 – We are excited to announce the release of BVGH’s WIPO Re:Search Annual Report. Across the board, we exceeded our 2017 goals for WIPO Re:Search. We look forward to building on these successes and continuing to drive product development for the most pressing global health needs in 2018.
(November 13, 2017) – The Government of Rwanda has joined the African Access Initiative (AAI), BVGH’s international public-private alliance addressing Africa’s escalating cancer crisis. Rwanda is the fifth African country to commit to AAI, joining Cameroon, Côte d’Ivoire, Kenya, and Nigeria. Expansion to fifth country demonstrates initiative’s relevance across Africa. Click here to read more.
(June 28, 2017) – In partnership with the African Organisation for Research and Training in Cancer (AORTIC) and key oncology leaders, BVGH released a white paper on the African continent’s emerging cancer crisis. The publication discusses cancer as a growing public health threat in Africa, the lack of funding and limited access to quality care that underlie the cancer crisis, and a call to action through public-private partnerships. Click here to read more.
(June 21, 2017) – BVGH is launching the African Access Initiative (AAI) at the Biotechnology Innovation Organization (BIO) International Convention in San Diego. AAI will expand access to oncology medicines and improve cancer care in Africa. Led by BVGH in partnership with Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., and the African Organisation for Research and Training in Cancer (AORTIC), AAI will expand access to oncology medicines and improve cancer care in Africa. Click here to read more.
(June 20, 2017) – Dr. Olufunmilayo (Funmi) Olopade, a native of Nigeria and founding director of the Center for Clinical Cancer Genetics at the University of Chicago, has dedicated her career to unraveling breast cancer biology in women of African descent. Her pioneering research, published in leading scientific journals, has shown that the disease “hits earlier and harder” in Africa than among Caucasian women in the United States. BVGH’s new African Access Initiative (AAI) will help address the cancer crisis and build the capacity and infrastructure needed to support further research on Africa’s cancer landscape and clinical trials of existing and new treatments. Dr. Olopade and Dr. Pol Vandenbroucke, Vice President of the Medical Strategy at Pfizer, will join BVGH’s Board of Directors to strengthen its expertise in oncology and healthcare delivery in Africa. Click here to read more.
(May 17, 2017) – In a press release today, BVGH announced that it will expand its programs to address the emerging cancer crisis in Africa. The African Access Initiative (AAI) will provide affordable, sustainable access to cancer therapeutics, enhance healthcare capacity, and foster cancer research in Africa. BVGH will launch its new initiative at the BIO International Convention in San Diego on June 21, 2017. Click here to read more.